Erratum: Hypoxia-Induced WSB1 promotes the metastatic potential of osteosarcoma cells (Cancer Research (2015) 75 (4839–4851) DOI: 10.1158/0008-5472.CAN-15-0711);Hypoxia-induced WSB1 promotes the metastatic potential of osteosarcoma cells

Cancer Research

Volumn 75, Issue 22, 2015, Pages 4839-4851

  Cao, Ji ^a   Wang, Yijie ^a   Dong, Rong ^a   Lin, Guanyu ^a   Zhang, Ning ^b   Wang, Jing ^b   Lin, Nengming ^c   Gu, Yongchuan ^d   Ding, Ling ^a   Ying, Meidan ^a   He, Qiaojun ^a   Yang, Bo ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c HANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

RAC1 PROTEIN; RHO GUANINE NUCLEOTIDE DISSOCIATION INHIBITOR 2; SUPPRESSOR OF CYTOKINE SIGNALING; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; WD REPEAT AND SOCS BOX CONTAINING 1; PROTEIN; SMALL INTERFERING RNA; WSB1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; METASTASIS POTENTIAL; MOUSE; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; RNA INTERFERENCE; ANIMAL; BAGG ALBINO MOUSE; BONE TUMOR; CELL HYPOXIA; CHROMATIN IMMUNOPRECIPITATION; CONFOCAL MICROSCOPY; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC TRANSDUCTION; METABOLISM; PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; TUMOR INVASION; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; BLOTTING, WESTERN; BONE NEOPLASMS; CELL HYPOXIA; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HETEROGRAFTS; HUMANS; MICE; MICE, INBRED BALB C; MICROSCOPY, CONFOCAL; NEOPLASM INVASIVENESS; OSTEOSARCOMA; PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TRANSDUCTION, GENETIC;

EID: 84955166266     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-20-1147     Document Type: Erratum

References (42)

1. Ritter J, Bielack SS. Osteosarcoma. Ann Oncol 2010;21(Suppl 7):vii320-5.
2. Bakhshi S, Radhakrishnan V. Prognostic markers in osteosarcoma. Expert Rev Anticancer Ther 2010;10:271-87.
3. Dai X, Ma W, He X, Jha RK. Review of therapeutic strategies for osteosarcoma, chondrosarcoma, and Ewing's sarcoma. Med Sci Monit 2011;17: RA177-90.
4. Kager L, Zoubek A, Potschger U, Kastner U, Flege S, Kempf-Bielack B, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2003;21:2011-8.
5. Miller BJ, Cram P, Lynch CF, Buckwalter JA. Risk factors for metastatic disease at presentation with osteosarcoma: an analysis of the SEER database. J Bone Joint Surg Am 2013;95:e89.
6. Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev 2006;32: 423-36.
7. Semenza GL. Oxygen sensing, homeostasis, and disease. N Engl J Med 2011;365:537-47.
8. Semenza GL. Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. Annu Rev Pathol 2014;9:47-71.
9. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011;11:393-410.
10. Keith B, Johnson RS, Simon MC. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 2012;12:9-22.
11. Yang QC, Zeng BF, Dong Y, Shi ZM, Jiang ZM, Huang J. Overexpression of hypoxia-inducible factor-1alpha in human osteosarcoma: correlation with clinicopathological parameters and survival outcome. Jpn J Clin Oncol 2007;37:127-34.
12. Chen Y, Yang Y, Yuan Z, Wang C, Shi Y. Predicting chemosensitivity in osteosarcoma prior to chemotherapy: An investigational study of biomarkers with immunohistochemistry. Oncol Lett 2012;3:1011-16.
13. El Naggar A, Clarkson P, Zhang F, Mathers J, Tognon C, Sorensen PH. Expression and stability of hypoxia inducible factor 1alpha in osteosarcoma. Pediatr Blood Cancer 2012;59:1215-22.
14. Guo M, Cai C, Zhao G, Qiu X, Zhao H, Ma Q, et al. Hypoxia promotes migration and induces CXCR4 expression via HIF-1alpha activation in human osteosarcoma. PLoS One 2014;9:e90518.
15. Majmundar AJ, Wong WJ, Simon MC. Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell 2010;40:294-309.
16. Archange C, Nowak J, Garcia S, Moutardier V, Calvo EL, Dagorn JC, et al. The WSB1 gene is involved in pancreatic cancer progression. PLoS ONE 2008;3:e2475.
17. Dentice M, Bandyopadhyay A, Gereben B, Callebaut I, Christoffolete MA, Kim BW, et al. The Hedgehog-inducible ubiquitin ligase subunit WSB-1 modulates thyroid hormone activation and PTHrP secretion in the developing growth plate. Nat Cell Biol 2005;7:698-705.
18. Choi DW, Seo YM, Kim EA, Sung KS, Ahn JW, Park SJ, et al. Ubiquitination and degradation of homeodomain-interacting protein kinase 2 by WD40 repeat/SOCS box protein WSB-1. J Biol Chem 2008;283:4682-9.
19. Zhang L, Zhou Q, Zhang N, Li W, Ying M, Ding W, et al. E2F1 impairs alltrans retinoic acid-induced osteogenic differentiation of osteosarcoma via promoting ubiquitination-mediated degradation of RARalpha. Cell Cycle 2014;13:1277-87.
20. Cao J, Ying M, Xie N, Lin G, Dong R, Zhang J, et al. The oxidation states of DJ-1 dictate the cell fate in response to oxidative stress triggered by 4-hpr: autophagy or apoptosis? Antioxidants & redox signaling 2014;21: 1443-59.
21. Kile BT, Schulman BA, Alexander WS, Nicola NA, Martin HM, Hilton DJ. The SOCS box: a tale of destruction and degradation. Trends Biochem Sci 2002;27:235-41.
22. Said N, Theodorescu D. Pathways of metastasis suppression in bladder cancer. Cancer Metastasis Rev 2009;28:327-33.
23. Dovas A, Couchman JR. RhoGDI: multiple functions in the regulation of Rho family GTPase activities. Biochem J 2005;390(Pt 1):1-9.
24. Walkley CR, Qudsi R, Sankaran VG, Perry JA, Gostissa M, Roth SI, et al. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev 2008;22:1662-76.
25. Z CZ, Luo C, Yang Z, Wang L. Heparanase participates in the growth and invasion of human U-2OS osteosarcoma cells and its close relationship with hypoxia-inducible factor-1alpha in osteosarcoma. Neoplasma 2010; 57:562-71.
26. Tong Y, Li QG, Xing TY, Zhang M, Zhang JJ, Xia Q. HIF1 regulates WSB-1 expression to promote hypoxia-induced chemoresistance in hepatocellular carcinoma cells. FEBS Lett 2013;587:2530-5.
27. Gilkes DM, Xiang L, Lee SJ, Chaturvedi P, Hubbi ME, Wirtz D, et al. Hypoxia-inducible factors mediate coordinated RhoA-ROCK1 expression and signaling in breast cancer cells. Proc Natl Acad Sci U S A 2014;111: E384-93.
28. Chen QR, Bilke S, Wei JS, Greer BT, Steinberg SM, Westermann F, et al. Increased WSB1 copy number correlates with its over-expression which associates with increased survival in neuroblastoma. Genes Chromosomes Cancer 2006;45:856-62.
29. Shichrur K, Feinberg-Gorenshtein G, Luria D, Ash S, Yaniv I, Avigad S. Potential role of WSB1 isoforms in growth and survival of neuroblastoma cells. Pediatr Res 2014;75:482-6.
30. Golovanov AP, Chuang TH, Der Mardirossian C, Barsukov I, Hawkins D, Badii R, et al. Structure-activity relationships in flexible protein domains: regulation of rho GTPases by RhoGDI and D4 GDI. J Mol Biol 2001;305: 121-35.
31. Plotnikov SV, Waterman CM. Guiding cell migration by tugging. Curr Opin Cell Biol 2013;25:619-26.
32. Ogden A, Rida PC, Aneja R. Heading off with the herd: how cancer cells might maneuver supernumerary centrosomes for directional migration. Cancer Metastasis Rev 2013;32:269-87.
33. Jaffe AB, Hall A. Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol 2005;21:247-69.
34. Boulter E, Garcia-Mata R. RhoGDI: A rheostat for the Rho switch. Small GTPases 2010;1:65-68.
35. Scheffzek K, Stephan I, Jensen ON, Illenberger D, Gierschik P. The Rac-RhoGDI complex and the structural basis for the regulation of Rho proteins by RhoGDI. Nat Struct Biol 2000;7:122-6.
36. Zhang Y, Rivera Rosado LA, Moon SY, Zhang B. Silencing of D4-GDI inhibits growth and invasive behavior in MDA-MB-231 cells by activation of Rac-dependent p38 and JNK signaling. J Biol Chem 2009;284: 12956-65.
37. Theodorescu D, Sapinoso LM, Conaway MR, Oxford G, Hampton GM, Frierson HF Jr. Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer. Clin Cancer Res 2004;10:3800-6.
38. Gildea JJ, Seraj MJ, Oxford G, Harding MA, Hampton GM, Moskaluk CA, et al. RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res 2002;62:6418-23.
39. Stevens EV, Banet N, Onesto C, Plachco A, Alan JK, Nikolaishvili-Feinberg N, et al. RhoGDI2 antagonizes ovarian carcinoma growth, invasion and metastasis. Small GTPases 2011;2:202-10.
40. Harding MA, Theodorescu D. RhoGDI2: a new metastasis suppressor gene: discovery and clinical translation. Urol Oncol 2007;25:401-6.
41. Agarwal NK, Chen CH, Cho H, Boulbes DR, Spooner E, Sarbassov DD. Rictor regulates cell migration by suppressing RhoGDI2. Oncogene 2013; 32:2521-6.
42. Agarwal NK, Kazyken D, Sarbassov dos D. Rictor encounters RhoGDI2: the second pilot is taking a lead. Small GTPases 2013;4:102-5.